Study on the effect of disease modifiers on pain, fatigue and quality of life in patients with NMOSD

Not Applicable

• Conditions: euromyelitis Optica Spectrum Disorders; NMOSD, Humanized monoclonal antibody, pain, fatigue, QOL; D009471; NMOSD, Humanized monoclonal antibody, pain, fatigue, QO

• Registration Number: JPRN-jRCT1030210419
• Lead Sponsor: Kazuhiro Ishii

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.

Exclusion Criteria

Minors (under 20 years old)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation / measurement of motor function, ADL, disability, QOL, pain, fatigue, and depressive symptoms